Information available on this platform may be relevant to researchers, students, biotechnology professionals, and individuals interested in current scientific research and innovation
Key Points Incomplete understanding of the pathogenesis of Parkinson disease (PD), lack of accurate animal models and validated biomarkers, and limitations in trial design impede the development of effective neuroprotective therapies for PD Novel transgenic animal models, adaptive and delayed-start trial designs, and identification of potential serum, cerebrospinal fluid and neuroimaging biomarkers are facilitating development and testing of effective disease-modifying therapies -Synuclein has a key role in the pathogenesis of PD
Highlights LifeMD, a telehealth company promoted by GLP-1 drugmaker Novo Nordisk, has urged its clinicians to see more patients and mete out prescriptions more rapidly, while providing little screening and follow-up, alleged five former employees in interviews and two lawsuits filed by former top leaders
In contrast to apoptosis, pyroptosis and necroptosis involve the leakage of cellular contents, which can activate the proinflammatory response and are classified as lytic forms of cell death